Evidence map›Paper›PMID 41367954›Full record

ReviewTherapeutic advances in medical oncology2025

Systemic and locoregional therapies for cutaneous metastases from breast cancer: state of art and new frontiers in treatment approach.

Francesco Russano, Davide Brugnolo, Michele Bottosso, Luigi Dall'Olmo, Paolo Del Fiore, Rino Baldan, Massimo Ferrucci, Noemi Musilli, Maria Vittoria Dieci, Valentina Guarneri and 2 more

Abstract readReview
In one paragraph

Review in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Francesco RussanoSoft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IRCCS, Padova, Italy.
Davide BrugnoloDepartment of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, Padua, Italy.
Michele BottossoDepartment of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, Padua, Italy.
Luigi Dall'OlmoSoft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IRCCS, Padova, Italy.
Paolo Del FioreSoft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IRCCS, Padova, Italy.ORCID https://orcid.org/0000-0002-2862-8014
Rino BaldanDepartment of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, Padua, Italy.
Massimo FerrucciBreast Surgical Unit, Veneto Institute of Oncology IRCCS, Via Gattamelata, 64, Padova 35121, Italy.ORCID https://orcid.org/0009-0006-4635-333X
Noemi MusilliBreast Surgical Unit, Veneto Institute of Oncology IRCCS, Padova, Italy.
Maria Vittoria DieciDepartment of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, Padua, Italy.
Valentina GuarneriDepartment of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, Padua, Italy.
Marco RastrelliSoft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IRCCS, Padova, Italy.
Simone MocellinSoft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IRCCS, Padova, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cutaneous metastases from breast cancer, although relatively uncommon, represent the most frequent form of skin metastases overall and pose a significant clinical and therapeutic challenge. Their presence classifies the disease as stage IV, typically prompting the initiation or modification of systemic treatment. However, current clinical guidelines do not distinguish between cutaneous and visceral metastases, which may lead to unnecessary alterations in systemic therapy-even when visceral disease remains well controlled-potentially compromising an otherwise effective regimen. This review provides a comprehensive overview of systemic and loco-regional treatment options for cutaneous breast cancer metastases, including current guidelines stratified by tumor subtype. Special attention is given to loco-regional therapies such as electrochemotherapy, radiotherapy, surgical excision, photodynamic therapy, intralesional agents, and topical treatments, all of which can be integrated with systemic therapy to improve local disease control, reduce symptoms, and enhance patient quality of life. We propose an integrated and personalized therapeutic model that combines systemic and loco-regional approaches, supported by a decision-making flowchart designed to assist clinicians in optimizing treatment strategies. By adopting a multidisciplinary perspective, this approach aims to improve both local and systemic disease management, clinical outcomes, and patient well-being. Further research is warranted to refine therapeutic combinations, establish standardized protocols, and fully realize the clinical benefits for patients with metastatic breast cancer presenting with cutaneous involvement.

Indexed as

breast cancerelectrochemotherapylocoregional therapyskin metastasessystemic therapy

Identifiers

PMID41367954
PMCPMC12682988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.